Disease · MONDO_0019165
central precocious puberty
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. central precocious puberty. Diseases, record MONDO_0019165. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019165
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- CPP, gonadotropin-dependant precocious puberty, gonadotropin-dependent precocious puberty, precocious puberty, central
- Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| HISTRELIN | CHEMBL1201255 | Protein | Approval | TTD | 2 | 1 | 1 | Drugs and targets |
| LEUPROLIDE ACETATE | CHEMBL1200775 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| TRIPTORELIN | CHEMBL1201334 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TRIPTORELIN PAMOATE | CHEMBL1200554 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LEUPROLIDE MESYLATE | CHEMBL4802223 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEUPROLIDE | CHEMBL1201199 | Protein | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets1
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes |
|---|---|---|---|---|---|
| GNRHR | Gonadotropin-releasing hormone receptor | 6 | Gonadotropin-releasing hormone receptor agonist | Approval | https://conductscience.org/library/genes/2798 |
Source Drugs and targets
Trials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02993926 | A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants | 108 | 2019-10-24 | Central Precocious Puberty | LEUPROLIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00635817 | A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty | Phase 3 | 84 | 2011-02-09 | Puberty, Precocious | LEUPROLIDE ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT00667446 | Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty | Phase 3 | 72 | 2013-12-10 | Precocious, Leuprolide Acetate, Luteinizing Hormone (LH), Gonadotrophin-releasing Hormone Agonist (GnRHa), Tanner Staging, Depot Formulation, Suppression of LH, Central Precocious Puberty (CPP), Gonadotrophin-releasing Hormone (GnRH), Lupron, GnRH Analog, Pediatrics Central Precocious Puberty | LEUPROLIDE ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT05029622 | A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty. | Phase 3 | 66 | 2024-05-28 | Central Precocious Puberty | TRIPTORELIN PAMOATE | Its record names the disease | ClinicalTrials.gov |
| NCT00660010 | Study of Lupron Depot In The Treatment of Central Precocious Puberty | Phase 3 | 55 | 2010-07-20 | Puberty, Precocious | LEUPROLIDE ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT03695237 | A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP) | Phase 3 | 45 | 2023-05-16 | Central Precocious Puberty (CPP) | LEUPROLIDE ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT01467882 | Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty | Phase 3 | 44 | 2015-09-04 | Central Precocious Puberty | TRIPTORELIN | Its record names the disease | ClinicalTrials.gov |
| NCT00779103 | Histrelin Subcutaneous Implant in Children With Central Precocious Puberty | Phase 3 | 36 | 2021-01-08 | Central Precocious Puberty | HISTRELIN | Its record names the disease | ClinicalTrials.gov |
| NCT04736602 | Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty. | Phase 3 | 32 | 2024-08-01 | Central Precocious Puberty | TRIPTORELIN PAMOATE | Its record names the disease | ClinicalTrials.gov |
| NCT05493709 | Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty | Phase 3 | 94 | Puberty; Precocious, Central | LEUPROLIDE MESYLATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials3
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Leuprolide Acetate 3M Depot 11.25 mg vs Leuprolide Acetate 3M Depot 30 mg: serious adverse events | 1 of 34 | 0 of 38 | 72 | NCT00667446 | Trial comparisons |
| Leuprolide Acetate - Previously Treated vs Leuprolide Acetate - Treament Naïve: deaths from any cause | 0 of 18 | 0 of 27 | 45 | NCT03695237 | Trial comparisons |
| Leuprolide Acetate - Previously Treated vs Leuprolide Acetate - Treament Naïve: serious adverse events | 0 of 18 | 1 of 27 | 45 | NCT03695237 | Trial comparisons |
Papers from its trials7
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019165
GET https://conductscience.org/api/diseases/v1/MONDO_0019165/drugs